Associated Papers
Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.
Kim TM et al.
Bmc Cancer, 2020
33287735 (PubMed )
Supplement: 12885_2020_7684_MOESM2_ESM.xlsx › Sheet1
HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.
Xue F et al.
Journal of Translational Medicine, 2015
26653219 (PubMed )
Supplement: 12967_2015_743_MOESM1_ESM.xlsx › Table_S4
Select a paper to view details